These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12638449)

  • 1. [Moxonidine is advantageous for hypertensive type 2 diabetic patients. Therapy of hypertension also lowers HbA1c].
    MMW Fortschr Med; 2003 Jan; 145(1-2):57. PubMed ID: 12638449
    [No Abstract]   [Full Text] [Related]  

  • 2. Moxonidine improves glycaemic control in mildly hypertensive, overweight type 2 diabetic patients.
    Cardiovasc J Afr; 2007; 18(4):271. PubMed ID: 17940677
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
    Jacob S; Klimm HJ; Rett K; Helsberg K; Häring HU; Gödicke J
    Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):315-22. PubMed ID: 15216449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
    Bakris GL; Fonseca V; Katholi RE; McGill JB; Messerli FH; Phillips RA; Raskin P; Wright JT; Oakes R; Lukas MA; Anderson KM; Bell DS;
    JAMA; 2004 Nov; 292(18):2227-36. PubMed ID: 15536109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
    Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
    J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.
    Gitt AK; Schmieder RE; Duetting E; Bramlage P; Schneider S; Tschöpe D;
    Cardiovasc Diabetol; 2012 Dec; 11():148. PubMed ID: 23216660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
    Kaaja R; Kujala S; Manhem K; Katzman P; Kibarskis A; Antikainen R; Ylihärsilä H; Erkkola R; Tuomilehto J
    Int J Clin Pharmacol Ther; 2007 Jul; 45(7):394-401. PubMed ID: 17725246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of antihypertensive agents from various pharmacological groups on blood pressure reaction during stress-testing. Part I. Comparative characteristics of medications, exerting effect of sympathoadrenal block].
    Praskurnichiĭ EA; Shevchenko OP; Makarova SV; Zhukova VA; Savel'eva SA
    Kardiologiia; 2008; 48(3):44-51. PubMed ID: 18429756
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
    Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
    Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Obesity and hypertension. A dangerous liaison].
    MMW Fortschr Med; 2002 Oct; 144(43):57. PubMed ID: 12534023
    [No Abstract]   [Full Text] [Related]  

  • 14. The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
    El-Naggar AR; Zaafar D; Elyamany M; Hassanin S; Bassyouni A; Abdel-Latif H
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):254-261. PubMed ID: 30630371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Beta blockers in hypertension treatment Will stepping back come soon?].
    Sawicki PT; Anlauf M; Haller H
    MMW Fortschr Med; 2007 Mar; 149(11):6. PubMed ID: 20104695
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypertension and diabetes - dangerous syntropy].
    Rett K
    MMW Fortschr Med; 2017 Oct; 159(18):42-45. PubMed ID: 29071615
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological properties of the central antihypertensive agent, moxonidine.
    Edwards LP; Brown-Bryan TA; McLean L; Ernsberger P
    Cardiovasc Ther; 2012 Aug; 30(4):199-208. PubMed ID: 21884003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular benefits of hypertension and glucose control in type 2 diabetes.
    van Rensburg BW
    Cardiovasc J Afr; 2008; 19(4):179-80. PubMed ID: 18776957
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of moxonidine in the treatment of arterial hypertension].
    Vachek J
    Vnitr Lek; 2021; 67(3):170-172. PubMed ID: 34171957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction: results of a pilot study.
    Piha J; Kaaja R
    Int J Impot Res; 2003 Aug; 15(4):287-9. PubMed ID: 12934058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.